智通财经网·2025-10-12 09:45Core Viewpoint - SystImmune, a wholly-owned subsidiary of Baillie Gifford (688506.SH), has entered into an exclusive licensing and collaboration agreement with Bristol-Myers Squibb (BMS) for the drug iza-bren (BL-B01D1, EGFR×HER3 dual antibody ADC), receiving an upfront payment of $800 million [1] Group 1 - The collaboration agreement includes a milestone payment of $250 million triggered by the completion of the global Phase II/III pivotal clinical trial IZABRIGHT-Breast01 [1] - SystImmune is expected to receive the $250 million milestone payment soon, subject to bank fees [1] - The agreement allows for additional potential payments of up to $2.5 billion in near-term or milestone payments, and up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1]